

E Burgos-Ramos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5718165/e-burgos-ramos-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

954
citations

14
h-index

28
g-index

28
ext. papers

1,082
ext. citations

5.7
avg. IF

3.63
L-index

#	Paper	IF	Citations
27	Cerebral Insulin Bolus Revokes the Changes in Hepatic Lipid Metabolism Induced by Chronic Central Leptin Infusion. <i>Cells</i> , 2021 , 10,	7.9	2
26	Olive oil and wine as source of multi-target agents in the prevention of Alzheimer disease.. <i>Nutrition Research Reviews</i> , 2021 , 1-43	7	1
25	Hydroxytyrosol improves mitochondrial energetics of a cellular model of Alzheimer's disease. <i>Nutritional Neuroscience</i> , 2020 , 1-11	3.6	6
24	Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's disease. <i>BioFactors</i> , 2017 , 43, 540-548	6.1	34
23	Selected Micronutrients in Cognitive Decline Prevention and Therapy. <i>Molecular Neurobiology</i> , 2016 , 53, 4083-4093	6.2	15
22	Improvement in glycemia after glucose or insulin overload in leptin-infused rats is associated with insulin-related activation of hepatic glucose metabolism. <i>Nutrition and Metabolism</i> , 2016 , 13, 19	4.6	8
21	Increased oxidative stress and apoptosis in the hypothalamus of diabetic male mice in the insulin receptor substrate-2 knockout model. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 573-83	4.1	14
20	One-week administration of hydroxytyrosol to humans does not activate Phase II enzymes. <i>Pharmacological Research</i> , 2015 , 95-96, 132-7	10.2	49
19	MYC/PGC-1 β Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. <i>Cell Metabolism</i> , 2015 , 22, 590-605	24.6	423
18	Chronic central leptin infusion modulates the glycemia response to insulin administration in male rats through regulation of hepatic glucose metabolism. <i>Molecular and Cellular Endocrinology</i> , 2015 , 415, 157-72	4.4	10
17	Acute up-regulation of the rat brain somatostatin receptor-effector system by leptin is related to activation of insulin signaling and may counteract central leptin actions. <i>Neuroscience</i> , 2013 , 252, 289-301	3.9	7
16	Leptin-induced downregulation of the rat hippocampal somatostatinergic system may potentiate its anorexigenic effects. <i>Neurochemistry International</i> , 2012 , 61, 1385-96	4.4	14
15	Central leptin and insulin administration modulates serum cytokine- and lipoprotein-related markers. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 1646-57	12.7	11
14	Adipose tissue promotes a serum cytokine profile related to lower insulin sensitivity after chronic central leptin infusion. <i>PLoS ONE</i> , 2012 , 7, e46893	3.7	9
13	Differential insulin receptor substrate-1 (IRS1)-related modulation of neuropeptide Y and proopiomelanocortin expression in nondiabetic and diabetic IRS2 $^{-/-}$ mice. <i>Endocrinology</i> , 2012 , 153, 1129-40	4.8	15
12	Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice. <i>PLoS ONE</i> , 2012 , 7, e29389	3.7	22
11	Chronic central leptin infusion modifies the response to acute central insulin injection by reducing the interaction of the insulin receptor with IRS2 and increasing its association with SOCS3. <i>Journal of Neurochemistry</i> , 2011 , 117, 175-85	6	22

10	Differential acute and chronic effects of leptin on hypothalamic astrocyte morphology and synaptic protein levels. <i>Endocrinology</i> , 2011 , 152, 1809-18	4.8	84
9	Evaluation of a multiplex assay for adipokine concentrations in obese children. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010 , 48, 1439-46	5.9	15
8	Regional and temporal differences in leptin signaling in rat brain. <i>General and Comparative Endocrinology</i> , 2010 , 167, 143-52	3	13
7	Sulfadiazine partially protects the rat temporal cortex from amyloid beta peptide (25-35)-induced alterations of the somatostatinergic system. <i>Neuroendocrinology</i> , 2009 , 89, 400-10	5.6	4
6	The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. <i>Journal of Neurochemistry</i> , 2009 , 109, 360-70	6	29
5	Minocycline prevents Abeta(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex. <i>Life Sciences</i> , 2009 , 84, 205-10	6.8	18
4	Somatostatin and Alzheimer's disease. <i>Molecular and Cellular Endocrinology</i> , 2008 , 286, 104-11	4.4	65
3	Minocycline provides protection against beta-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. <i>Neuroscience</i> , 2008 , 154, 1458-66	3.9	34
2	Chronic but not acute intracerebroventricular administration of amyloid beta-peptide(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus. <i>Journal of Neuroscience Research</i> , 2007 , 85, 433-42	4.4	14
1	Effects of single and continuous administration of amyloid beta-peptide (25-35) on adenyl cyclase activity and the somatostatinergic system in the rat frontal and parietal cortex. <i>Neuroscience</i> , 2005 , 135, 181-90	3.9	13